france-health-policy

fortune.com

Drug Doubles Survival in Metastatic Pancreatic Cancer Trial

An international trial presented Sunday showed daraxonrasib doubled median survival for patients with metastatic pancreatic cancer compared with standard chemotherapy. France has expanded a personalized screening program to eight additional centers.

3 sources